Oklahoma 2025 Regular Session

Oklahoma Senate Bill SB927 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2		-	~~SB927 HFLR Page 1~~
3		-	~~BOLD FACE denotes Committee Amendments.~~ 1
	2	+
	3	+	ENGR. S. B. NO. 927 Page 1 1
4	4		2
5	5		3
6	6		4
7	7		5
8	8		6
9	9		7
10	10		8
11	11		9
12	12		10
13	13		11
14	14		12
15	15		13
16	16		14
17	17		15
18	18		16
19	19		17
20	20		18
21	21		19
22	22		20
23	23		21
24	24		22
25	25		23
26	26		24
27		-
28		-	HOUSE OF REPRESENTATIVES - FLOOR VERSION
29		-
30		-	STATE OF OKLAHOMA
31		-
32		-	1st Session of the 60th Legislature (2025)
33	27
34	28		ENGROSSED SENATE
35	29		BILL NO. 927 By: Hicks of the Senate
36	30
37	31		and
38	32
39	33		Munson of the House
40	34
41	35
42	36
43	37
44	38		An Act relating to the state Medicaid program;
45	39		amending 63 O.S. 2021, Section 5030.1, which relates
46	40		to the Medicaid Drug Utilization Review Board;
47	41		modifying appointmen t procedure for certain members;
48	42		updating statutory language; and providing an
49	43		effective date.
50	44
51	45
52	46
53	47
54	48
55	49
56	50		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
57	51		SECTION 1. AMENDATORY 63 O.S. 2021, Section 5030.1, is
58	52		amended to read as f ollows:
59	53		Section 5030.1. A. There is hereby created within the Oklahoma
60	54		Health Care Authority the Medicaid Drug Utilization Review Board,
61	55		which shall be responsible for the development, implementation and
62	56		assessment of retrospective and prospective drug u tilization
63	57		programs under the direction of the Authority.
64		-	SB927 HFLR Page 2
65		-	BOLD FACE denotes Committee Amendments. 1
	58	+	B. The Medicaid Drug Utilization Re view Board shall consist of
	59	+	ten (10) members appointed by the administrator of the Authority as
	60	+	follows:
	61	+
	62	+	ENGR. S. B. NO. 927 Page 2 1
66	63		2
67	64		3
68	65		4
69	66		5
70	67		6
71	68		7
72	69		8
73	70		9
74	71		10
75	72		11
76	73		12
77	74		13
78	75		14
79	76		15
80	77		16
81	78		17
82	79		18
83	80		19
84	81		20
85	82		21
86	83		22
87	84		23
88	85		24
89	86
90		-	B. The Medicaid Drug Utilization Review Board shall consist of
91		-	ten (10) members appointed by the administrator of the Authority as
92		-	follows:
93	87		1. Four physicians, licensed and actively engaged in the
94	88		practice of medicine or osteopathic medicine in this state, of
95	89		which:
96	90		a. three shall be physicians , each of whom is chosen from
97	91		a list of not less than six three names submitted by
98	92		the Oklahoma State Medical Association, and
99	93		b. one shall be a physician ch osen from a list of not
100	94		less than two names submitted by the Oklahoma
101	95		Osteopathic Association;
102	96		2. Four licensed pharmacists actively engaged in the practice
103	97		of pharmacy, chosen from a list of not less than six names submitted
104	98		by the Oklahoma Pharmaceutical Pharmacists Association;
105	99		3. One person representing the lay community, who shall not be
106	100		a physician or a pharmacist, but shall be a health care professional
107	101		with recognized knowledge and expertise in at least one of the
108	102		following:
109	103		a. clinically appropriate prescribing of covered
110	104		outpatient drugs,
111	105		b. clinically appropriate dispensing and monitori ng of
112	106		covered outpatient drugs,
113	107		c. drug use review, evaluation and intervention, and
114		-	SB927 HFLR Page 3
115		-	BOLD FACE denotes Committee Amendments. 1
	108	+	d. medical quality assurance; and
	109	+	4. One person representing the pharmaceuti cal industry who is a
	110	+	resident of the State of Oklahoma this state, chosen from a list of
	111	+
	112	+	ENGR. S. B. NO. 927 Page 3 1
116	113		2
117	114		3
118	115		4
119	116		5
120	117		6
121	118		7
122	119		8
123	120		9
124	121		10
125	122		11
126	123		12
127	124		13
128	125		14
129	126		15
130	127		16
131	128		17
132	129		18
133	130		19
134	131		20
135	132		21
136	133		22
137	134		23
138	135		24
139	136
140		-	d. medical quality assurance; and
141		-	4. One person representing the pharmaceuti cal industry who is a
142		-	resident of the State of Oklahoma this state, chosen from a list of
143	137		not less than two names submitted by the Pharmaceutical Research and
144	138		Manufacturers of America. The member representing the
145	139		pharmaceutical industry shall be prohibite d from voting on action
146	140		items involving drugs or classes of drugs.
147	141		C. Members shall serve ter ms of three (3) years, except that
148	142		one physician, one pharmacist and the lay representative shall each
149	143		be initially appointed for two -year terms in order to stagg er the
150	144		terms. In making the appointments, the administrator shall provide,
151	145		to the extent possible, for geographic balance in the representation
152	146		on the Medicaid Drug Utilization Review Board. Members may be
153	147		reappointed for a period not to exceed three thr ee-year terms and
154	148		one partial term. Vacancies on the Medicaid Drug Utilization Review
155	149		Board shall be filled for the balance of the unexpired term from new
156	150		lists submitted by the entity originally submitting the list for the
157	151		position vacated.
158	152		D. The Medicaid Drug Utilization Review Board shall elect from
159	153		among its members a chair and a vice-chair vice chair who shall
160	154		serve one-year terms, provided they may succeed themselves.
161	155		E. The proceedings of all meetings of the Medicaid Drug
162	156		Utilization Review Board shall comply with the provisions of the
163		-	SB927 HFLR Page 4
164		-	BOLD FACE denotes Committee Amendments. 1
	157	+	Oklahoma Open Meeting Act and shall be subject to the provisions of
	158	+	the Administrative Procedures Act.
	159	+	F. The Medicaid Drug Utilization Review Board may advise and
	160	+	make recommendations to the Authority regarding ex isting, proposed
	161	+
	162	+	ENGR. S. B. NO. 927 Page 4 1
165	163		2
166	164		3
167	165		4
168	166		5
169	167		6
170	168		7
171	169		8
172	170		9
173	171		10
174	172		11
175	173		12
176	174		13
177	175		14
178	176		15
179	177		16
180	178		17
181	179		18
182	180		19
183	181		20
184	182		21
185	183		22
186	184		23
187	185		24
188	186
189		-	Oklahoma Open Meeting Act and shall be subject to the provisions of
190		-	the Administrative Procedures Act.
191		-	F. The Medicaid Drug Utilization Review Board may advise and
192		-	make recommendations to the Authority regarding ex isting, proposed
193	187		and emergency rules governing retrospective and prospective drug
194	188		utilization programs. The Oklahoma Health Care Authority Board
195	189		shall promulgate rules pursuant to the provisions of the
196	190		Administrative Procedures Act for implementation of t he provisions
197	191		of this section.
198	192		SECTION 2. This act shall become effective Nov ember 1, 2025.
	193	+	Passed the Senate the 17th day of March, 2025.
199	194
200		-	COMMITTEE REPORT BY: COMMITTEE ON HEALTH AND HUMAN SERVICES, dated
201		-	04/16/2025 – DO PASS.
	195	+
	196	+
	197	+	Presiding Officer of the Senate
	198	+
	199	+
	200	+	Passed the House of Representatives the ____ day of _________ _,
	201	+	2025.
	202	+
	203	+
	204	+
	205	+	Presiding Officer of the House
	206	+	of Representatives
	207	+